Randall Stanicky

In a report published Tuesday, Canaccord Genuity analyst Randall Stanicky lowered the price target on Allergan (NYSE: AGN) from $111 to $98 and reiterated a Hold rating on the company. In the report, Canaccord Genuity commented, "With yesterday’s 12% RESTASIS driven sell-off, AGN shares are...

Goldman Sachs analysts Randall Stanicky, Gregory Waterman and Stephan Stewart maintained their CL-Buy rating for shares of Allergan Inc (NYSE: AGN) The analysts said that their meetings with physicians confirmed improving demand trends and said that Allergan Inc remains one of their top investing...

Goldman Sachs analysts Randall Stanicky, Gregory Waterman and Stephan Stewart maintained their Neutral rating for shares of Medicis Pharmaceutical Corp (NYSE: MRX) and lowered the price target to $27 per share, down from the previous price target of$28. The analysts said that an informal poll of...

Goldman Sachs analysts Randall Stanicky, Stephan Stewart and Gregory Waterman commented on the FDA's denial of a Citizen Petition (CP) from Teva Pharmaceutical Industries (Nasdaq: TEVA) that requested that the FDA not approve any ANDA applications for a generic Copaxone unless specific requirements...